Introduction

The objective of the meeting was to bring together scientists with an interest in inflammation research, and to encourage the communication and discussion of recent advances and results – ranging from early research findings to clinical data. Attendees heard from world-class speakers who discussed new therapeutic approaches for the treatment of the wide range of serious diseases driven by underlying inflammatory processes.

Programme 

09.00  Registration and refreshments

09.25  Introduction

09.30  Epigenetic modulation for the future treatment of inflammatory disease

          Prof Peter Barnes, Head of Respiratory Medicine, National Heart and Lung Institute (Imperial College London)   

10.30  Identification of potent and selective molecule inhibitors of the BET family bromodomains demonstrate the tractability of a new class of epigenetic targets for drug discovery

          Dr Chun-wa Chung, Section Leader of Biophysical and Structural Analysis Group (GlaxoSmithKline R&D)  

11.10  Refreshments

11.40  Agonism at prostacyclin receptors in the treatment of PAH

          Keith J Morrison (Actelion)

12.20  Identification of ALK5 inhibitors for the treatment of PAH

          Dr Duncan Shaw (Novartis Institutes for Biomedical Research)

13.00   Lunch

14.00   The discovery of novel TLR7 agonists

          Tom McInally, Team Leader (AstraZeneca)

14.40  The discovery of CDP323, a novel and potent Inhibitor of the integrins α4β1 (VLA-4) and α4β7

          Dr Julien Brown, Principal Scientist (UCB Celltech)

15.20   Refreshments

15.50   JAK inhibitors as novel anti-inflammatory agents

           Dr Iain Kilty, Director, Allergy and Respiratory Research Unit (Pfizer Global Research and Development)

16.30   Generation and development of a series of MAPKAPK5 inhibitors for the treatment of rheumatoid arthritis

           Dr Martin J I Andrews, Group Leader (Galapagos NV)

17.10   Close